Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 6, 2009, Pages 651-658

  Panetta, J C ^a,b   Gajjar, A ^a,b   Hijiya, N ^a,b   Hak, L J ^b   Cheng, C ^a   Liu, W ^a   Pui, C H ^a,b   Relling, M V ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINE; ERWINIA ASPARAGINASE; ESCHERICHIA COLI ASPARAGINASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MATHEMATICAL MODEL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTIBODIES; ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARAGINE; COMPUTER SIMULATION; ESCHERICHIA COLI; HUMANS; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECOMBINANT PROTEINS; RECURRENCE; TREATMENT FAILURE;

EID: 70450245172     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.162     Document Type: Article

References (35)

1. Capizzi, R.L. et al. l-Asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann. Intern. Med. 74, 893-901 (1971).
2. Jones, B. et al. Optimal use of l-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med. Pediatr. Oncol. 3, 387-400 (1977).
3. Clavell, L.A. et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N. Engl. J. Med. 315, 657-663 (1986).
4. Asselin, B.L. et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by l-asparaginase. Cancer Res. 49, 4363-4368 (1989).
5. Schorin, M.A. et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J. Clin. Oncol. 12, 740-747 (1994).
6. Boos, J. et al. Monitoring of asparaginase activity and asparagine levels in children on diferent asparaginase preparations. Eur. J. Cancer 32A, 1544-1550 (1996). (Pubitemid 26279122)
7. Vieira Pinheiro, J.P. et al. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br. J. Haematol. 113, 115-119 (2001).
8. Avramis, V.I. et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99, 1986-1994 (2002).
9. Panosyan, E.H. et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J. Pediatr. Hematol. Oncol. 26, 217-226 (2004).
10. Jarrar, M. et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in frst bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr. Blood Cancer 47, 141-146 (2006).
11. Hawkins, D.S. et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated l-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin. Cancer Res. 10, 5335-5341 (2004).
12. Asselin, B.L. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv. Exp. Med. Biol. 457, 621-629 (1999).
13. Avramis, V.I. & Panosyan, E.H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin. Pharmacokinet. 44, 367-393 (2005).
14. Woo, M.H. et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 18, 1525-1532 (2000).
15. Stams, W.A. et al. Asparagine synthetase expression is linked with l-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 105, 4223-4225 (2005).
16. Appel, I.M., den Boer, M.L., Meijerink, J.P., Veerman, A.J., Reniers, N.C. & Pieters, R. Up-regulation of asparagine synthetase expression is not linked to the clinical response l-asparaginase in pediatric acute lymphoblastic leukemia. Blood 107, 4244-4249 (2006).
17. Hijiya, N. et al. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acut lymphoblastic leukemia in frst relapse. Cancer 112, 1983-1991 (2008).
18. Asselin, B.L., Whitin, J.C., Coppola, D.J., Rupp, I.P., Sallan, S.E. & Cohen, H.J. Comparative pharmacokinetic studies of three asparaginase preparations. J. Clin. Oncol. 11, 1780-1786 (1993).
19. Appel, I.M. et al. Lack of asparagine depletion in the cerebrospinal fuid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 17, 2254-2256 (2003).
20. Hak, L.J. et al. Asparaginase pharmacodynamics difer by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18, 1072-1077 (2004).
21. Abshire, T.C., Pollock, B.H., Billett, A.L., Bradley, P. & Buchanan, G.R. Weekly polyethylene glycol conjugated l-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96, 1709-1715 (2000).
22. Andrulis, I.L., Argonza, R. & Cairney, A.E. Molecular and genetic characterization of human cell lines resistant to l-asparaginase and albizziin. Somat. Cell Mol. Genet. 16, 59-65 (1990).
23. Hutson, R.G., Kitoh, T., Moraga Amador, D.A., Cosic, S., Schuster, S.M. & Kilberg, M.S. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am. J. Physiol. 272, C1691-C1699 (1997).
24. Aslanian, A.M. & Kilberg, M.S. Multiple adaptive mechanisms afect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem. J. 358, 59-67 (2001).
25. Aslanian, A.M., Fletcher, B.S. & Kilberg, M.S. Asparagine synthetase expression alone is sufcient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem. J. 357, 321-328 (2001).
26. Fine, B.M., Kaspers, G.J., Ho, M., Loonen, A.H. & Boxer, L.M. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res. 65, 291-299 (2005).
27. Iwamoto, S., Mihara, K., Downing, J.R., Pui, C.H. & Campana, D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. 117, 1049-1057 (2007). (Pubitemid 46556761)
28. Cooney, D.A., Capizzi, R.L. & Handschumacher, R.E. Evaluation of l-asparagine metabolism in animals and man. Cancer Res. 30, 929-935 (1970).
29. Woo, M.H. et al. Cerebrospinal fuid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J. Clin. Oncol. 17, 1568-1573 (1999).
30. Wang, B., Hak, L.J., Relling, M.V., Pui, C.H., Woo, M.H. & Storm, M.C. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J. Immunol. Methods 239, 75-83 (2000).
31. NONMEM Users' Guide Part I-VIII. San Francisco, CA, NONMEM Project Group, University of California at San Francisco (1998).
32. Holcenberg, J.S. Enzymes as drugs. Annu. Rev. Pharmacol. Toxicol. 17, 97-116 (1977).
33. Avramis, V.I. & Spence, S.A. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J. Pediatr. Hematol. Oncol. 29, 239-247 (2007).
34. Riccardi, R., Holcenberg, J.S., Glaubiger, D.L., Wood, J.H. & Poplack, D.G. L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fuid of rhesus monkeys and humans. Cancer Res. 41, 4554-4558 (1981).
35. D'Argenio, D.Z. & Schumitzky, A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles, Biomedical Simulations Resource (1997).